- Previous Close
3.440 - Open
3.410 - Bid 3.380 x --
- Ask 3.400 x --
- Day's Range
3.310 - 3.430 - 52 Week Range
3.030 - 5.060 - Volume
11,058,000 - Avg. Volume
5,149,605 - Market Cap (intraday)
10.032B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
9.44 - EPS (TTM)
0.360 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.18 (5.09%)
- Ex-Dividend Date May 20, 2025
- 1y Target Est
5.13
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
www.ssygroup.com.hk6,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2005.HK
View MorePerformance Overview: 2005.HK
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2005.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2005.HK
View MoreValuation Measures
Market Cap
10.15B
Enterprise Value
12.50B
Trailing P/E
9.61
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.77
Price/Book (mrq)
1.41
Enterprise Value/Revenue
2.16
Enterprise Value/EBITDA
8.50
Financial Highlights
Profitability and Income Statement
Profit Margin
18.38%
Return on Assets (ttm)
6.84%
Return on Equity (ttm)
14.53%
Revenue (ttm)
5.77B
Net Income Avi to Common (ttm)
1.06B
Diluted EPS (ttm)
0.360
Balance Sheet and Cash Flow
Total Cash (mrq)
1.29B
Total Debt/Equity (mrq)
48.30%
Levered Free Cash Flow (ttm)
--